. Molecular and phenotypic dissection of gp130 signaling in the cardiac myocyte. Cytokine binding to its cognate receptor induces dimerization with the gp130 receptor, resulting in parallel activation of Janus kinase (JAK), Ras and phosphatidyl inositol kinase pathways, all dependent on different intracellular regions of the gp130 receptor. Each of the pathways initiated have been demonstrated to be able to evoke a hypertrophic response, but also have intrinsic cell survival characteristics. STAT3b constitutes the potential dominant negative form of STAT3 and may inhibit both hypertrophic and anti-apoptotic effects elicited by several other STAT isoforms.
transplant material of ischemic heart disease (IHD). Given 2 . Cardiac signaling: the good, the bad and where the limitations of the source (human transplant material), STAT may fit in the quality of their Western blot data is admirable. The differential activation pattern of STAT isoforms in DCM Ng et al. [10] make the logical inference from their and IHD is consistent with the notion that cardiac remodelfindings of persistent activation of several STAT isoforms ing is not associated with global activation of signal in chronic heart failure that inhibition of cytokine signaling transducers, but rather characterized by select activation of might prove beneficial in preventing aspects of decompendiscrete pathways, depending on heart failure etiology and sated hypertrophy and heart failure. However, it is becomoriginal insult. The correlation between previously reing increasingly clear that qualitatively distinct forms of ported elevated cytokine levels in heart tissue and circulathypertrophy signals exist in parallel, both during initial and ing plasma during end-stage failure [4] [5] [6] , and their later stages of cardiac remodeling, and some signals, findings of differential STAT activation in human DCM / including those for cell survival itself, are beneficial and IHD material, reinforces the authors to speculate on antimay prevent / delay the transition to decompensation. The cytokine treatment in human heart failure [10] . most compelling evidence in support of latter view stems Does the gp130 receptor / JAK / STAT axis truly reprefrom a study using mice with ventricular chamber-resents a previously unnoticed therapeutic target, or is the stricted deletion of the gp130 receptor, of all genes. These involvement of this pathway in failure progression more animals have a normal cardiac structure and function and a complex and as a therapeutic device but an imaginary normal life span in the absence of environmental stress, but dagger, one that exists only in our mind ? in response to aortic pressure overload these mice display rapid onset of dilated cardiomyopathy and massive induc-STAT-induced STAT inhibitor [SSI] family) consist of tion of myocyte apoptosis versus the control mice that eight members (CIS and SOCS1-7). Functionally, CIS and exhibit 'compensatory' hypertrophy [11] . The unequivocal, SOCS1-3 proteins interact with cytokine receptors and / or genetic evidence from this study indicates that myocyte JAKs, thereby inhibiting activation of kinases and STATs. apoptosis, at least in this experimental setting, is a crucial SOCS3, the intrinsic inhibitor of JAK, was recently shown phenomenon in the transition between the early phases of to display a biphasic induction in response to pressure hypertrophy and heart failure, and, consequently, stimulaoverload stimuli in the mouse, and its induction was tion of gp130-dependent signals may result to be protective closely correlated with STAT3 phosphorylation, as well as in the setting of heart failure following biomechanical other parameters of hypertrophy, suggesting that cardiac stress [11] .
gp130 / JAK / STAT signaling is precisely controlled by this In further support of this concept, several genetic endogenous suppressor. This notion is further reinforced models now exist of hypertrophy that is well tolerated or by the fact that viral-mediated gene transfer of SOCS3 to even beneficial. The mitogen-activated protein kinase ventricular cardiomyocytes completely suppressed both (MAPK) superfamily culminates in three subfamilies of hypertrophy and antiapoptotic phenotypes induced by LIF terminal effector kinases: extracellular signal-regulated [14] . protein kinase (ERK1 / 2 and ERK5), c-jun NH -terminal
The group of Bogoyevitch [10] compared the general 2 MAPK kinase (JNK), and p38
. Specific activation of ERK1 / phosphotyrosine status between control and IHD/ DCM 2 by a kinase that lies upstream caused concentric hyhuman hearts and noted marked phosphorylation of several pertrophy without decompensation accompanied by markhigh molecular mass proteins in failure samples, consistent ed resistance to apoptotic cell death [12] . Likewise, the in size of (cytokine) receptors. This change in receptor PI3K /Akt pathway can promote cardiac myocyte growth tyrosine phosphorylation correlates well with their noted that is perhaps more physiological and associated with upregulation of STAT phosphorylation, suggesting that cardioprotection in cell culture and in mice [13] . And upstream controlling pathways, rather than an absence of finally, selective activation of STAT3a itself in the murine intrinsic STAT inhibitors such as SOCS, may predominate heart causes concentric hypertrophy with marked resistthe activation of STAT. This delicate balance between ance against doxirubicin-induced cardiomyopathy [14] , upstream (receptor) and downstream (SOCS) regulators of which may be the result of its documented potential to the pathway should become a future experimental goal in upregulate notorious cytoprotectors as Bcl-XL, VEGF and the form of an identification of the specific tyrosinemanganese superoxide dismutase (MnSOD) [15] . hyperphosphorylated receptor(s) and an assessment of By sharp contrast, a catastrophic cardiomyopathy is SOCS expression levels during the progression to failure.
MAPK
evoked by selective activation of either the p38 [16] Perhaps the most intriguing observation of the study of 21 Ng et al. [10] , at least from a mechanistic point of view, or ERK5-terminal branch of MAPK [17] , and the Ca -21 was the identification of STAT3b, not STAT3a, as the dependent transducers calcineurin [18] and Ca -calhyperphosphorylated STAT3 isoform in end-stage failure modulin dependent protein kinase (CamK) [19] in transmaterial. These a and b isoforms are spliceforms from the genic mice, thus incriminating these effectors more so than single STAT3 gene, with 3b being a C-terminal truncation e.g. ERK1 / 2 MAPK, PI3K-Akt or JAK-STAT signaling as of STAT3a. Importantly, earlier, non-cardiac studies have targets for drug development in heart failure. Therefore, demonstrated that STAT3b is able to bind STAT consenaccurate assessment of who is 'good' and who is 'bad' in sus binding sites in regulatory DNA of STAT-responsive ventricular remodelling now seems more relevant than ever genes, yet failed to activate transcription, suggesting that in the present era of new molecular phenotypes.
the STAT3b isoform, highly activated in the failing human Is this then the final verdict on the gp130 / JAK / STAT heart, may function in a dominant negative fashion toward signaling axis? Should we promote cytokine signals rather other STAT members [20] . Although latter contention than inhibit them as a treatment to heart failure? Not quite, remains to be thoroughly investigated in the cardiac this pathway comprises yet a third level of complexity.
setting, it is tempting to speculate that a STAT3b prodeath pathway may be preferentially activated at the final stages of heart failure progression. Whether activation of 3 . gp130 signaling: inherent negative feedback signals inhibitory STAT3b constitutes a determinant in the transition to decompensation, and what the molecular mechaRegulation of the JAK signaling pathway takes place at nism underlies the obviate switch from STAT3a to 3b several levels, including receptor internalization, dephosactivation, remains to explored. phorylation by protein phosphatases, degradation by the All in all, this particular study provides a platform for in proteasome pathway, and by a recently discovered family depth studies to define the precise involvement of the of cytokine-inducible inhibitors of cytokine signaling. This gp130 / JAK / STAT axis in regulating heart failure. As for suppressor of cytokine signaling (SOCS) family (also the Cardiovascular Scientist, our attitude toward this referred to as cytokine-inducible SH2 protein [CIS] or pathway and its role in disease development is reminiscent
